Phase 1

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Alkermes) ALK4230-A101A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid TumorsHirte, Dr HalOpen to recruitmentNCT02799095
(BI) 1381.1 / REFMAL 473An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics, and efficacy of BI 754091 in patients with advanced solid tumours Hirte, Dr HalOpen to recruitmentNCT02952248
(BMS) CA209848 / CheckMate 848A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or
Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High
Tumor Mutational Burden (TMB-H)
Hotte, Dr SebastienOpen to recruitmentNCT03668119
(CCTG) IND.228A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare TumoursHirte, Dr HalOpen to recruitmentNCT02879162
(Fusion) FPX-01-01A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid TumoursJuergens, Dr RosalynOpen to recruitmentNCT03746431
(CCTG) IND.235 / CRI-CCTG-0001 / NIMBLeA Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based AssayHirte, Dr HalSuspended/On holdNCT03461952
Download PDF